Galimedix Therapeutics
Manufacturing · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3704 Calvend Ln, Kensington, Maryland, 2...Website
www.galimedix.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Galimedix Therapeutics
Galimedix Therapeutics is focused on developing innovative drugs to treat major neurodegenerative diseases, particularly those involving amyloid beta, such as dry age-related macular degeneration, glaucoma, and Alzheimer's disease. Their lead candidate, GAL-101, is currently in Phase 2 clinical testing for dry AMD and aims to block a key step in the neurodegenerative process with minimal side effects. The company designs its product candidates for convenient administration, making them patient-friendly and less burdensome on healthcare systems. Galimedix is committed to improving the lives of patients worldwide by addressing the root causes of these debilitating conditions.Explore more
Galimedix Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Galimedix Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Galimedix Therapeutics launches new products
Check out if Galimedix Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Galimedix Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Galimedix Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Galimedix Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Galimedix Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Galimedix Therapeutics recently announced quarterly report
Galimedix Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Galimedix Therapeutics
Compare insights from companies similar to Galimedix Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Galimedix Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Galimedix Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Galimedix Therapeutics.
Galimedix Therapeutics Tech Stack
A closer look at the technologies used by Galimedix Therapeutics
Galimedix Therapeutics News & Media
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
Kensington, MD, USA and Munich/Martinsried, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open InnovationGalimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
Kensington, MD, USA and Munich/Martinsried, Germany, March 05, 2026 (GLOBE NEWSWIRE) -- Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 ConferenceGalimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Kensington, MD, USA and Munich/Martinsried, Germany, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
KENSINGTON, Md. and MUNICH and MARTINSRIED, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and retinal diseases, today announced the completion of its Phase 1 study with orally administered GAL-101, a small molecule specifically designed to target misfolded amyloid beta (Aβ) monomers.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Galimedix Therapeutics
Sign Up For FreeTo access detailed company insights
Galimedix Therapeutics is focused on developing innovative drugs to treat major neurodegenerative diseases, particularly those involving amyloid beta, such as dry age-related macular degeneration, glaucoma, and Alzheimer's disease. Their lead candidate, GAL-101, is currently in Phase 2 clinical testing for dry AMD and aims to block a key step in th... Read More
